Savara Inc
SVRAHealthcare|Biotechnology|USA
$6.03
-0.26 (-4.06%)
Tangible Book
$0.80
Earnings Power
$0.88
Financials
Financial Snapshot
Market Cap
$1.24B
Enterprise Value
$172.7M
Revenue (TTM)
$0.00
Net Income (TTM)
$-129.5M
Cash & Equivalents
—
Net Cash/Share
$0.77
Free Cash Flow (TTM)
$-107.0M
Operating CF (TTM)
$-106.9M
Debt/Equity
0.17
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$26.7M
Monthly Burn
$8.9M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $13.4M | $94.3M | $110.8M | $121.8M | $82.2M | $161.2M | $125.9M | $162.3M | $196.3M | $235.7M | $202.8M | |
| Operating Cash Flow | $-8.4M | $-28.2M | $-39.3M | $-45.1M | $-39.8M | $-40.1M | $-34.6M | $-51.1M | $-89.1M | $-101.0M | $-106.9M | |
| Free Cash Flow | $-8.4M | $-28.7M | $-39.4M | $-45.3M | $-43.1M | $-40.1M | $-34.6M | $-51.4M | $-89.1M | $-101.1M | $-107.0M | |
| Capital Expenditure | $-8.0K | $-495.0K | $-141.0K | $-148.0K | $-3.3M | $-57.0K | $-9.0K | $-296.0K | $-25.0K | $-22.0K | $-73.0K | |
| Financing Cash Flow | $5.1M | $106.1M | $55.2M | $54.9M | $3.7M | $120.8M | $87.0K | $82.8M | $117.6M | $137.8M | $135.3M |
R&D Spending
R&D (TTM)
$85.6M
R&D Intensity
—
R&D Growth YoY
+5.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400.0K | $0.00 | $0.00 | $0.00 | $257.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $8.2M | $18.5M | $37.2M | $38.8M | $35.0M | $29.0M | $27.9M | $44.3M | $78.0M | $81.4M | $85.6M | |
| R&D % of Revenue | 2045.5% | — | — | — | 13633.5% | — | — | — | — | — | — | |
| SG&A | $2.8M | $11.1M | $10.7M | $13.1M | $14.3M | $12.3M | $10.9M | $15.7M | $25.0M | $42.1M | $48.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400.0K | $0.00 | $0.00 | $0.00 | $257.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $400.0K | $0.00 | $0.00 | $0.00 | $257.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $8.2M | $18.5M | $37.2M | $38.8M | $35.0M | $29.0M | $27.9M | $44.3M | $78.0M | $81.4M | $85.6M | |
| SG&A | $2.8M | $11.1M | $10.7M | $13.1M | $14.3M | $12.3M | $10.9M | $15.7M | $25.0M | $42.1M | $48.4M | |
| Operating Income | $-10.9M | $-30.0M | $-46.9M | $-51.0M | $-48.4M | $-40.6M | $-38.0M | $-59.2M | $-102.4M | $-122.8M | $-133.3M | |
| Interest Expense | $-452.0K | $-1.2M | $0.00 | $-70.0K | $-1.5M | $-2.3M | $-88.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-11.3M | $-33.4M | $-68.6M | $-78.2M | $-49.6M | $-43.0M | $-38.1M | $-54.7M | $-95.9M | $-118.8M | $-129.5M | |
| Net Income | $-10.9M | $-29.8M | $-61.5M | $-78.2M | $-49.6M | $-43.0M | $-38.1M | $-54.7M | $-95.9M | $-118.8M | $-129.5M | |
| EPS (Diluted) | -5.62 | -1.76 | -1.85 | -1.95 | -0.84 | -0.32 | -0.25 | -0.33 | -0.48 | -0.53 | -0.56 | |
| EBITDA | $-10.5M | $-29.6M | $-46.4M | $-77.1M | $-47.4M | $-40.4M | $-37.9M | $-59.1M | $-102.3M | $-122.7M | $-133.0M | |
| Shares Out. (M) | 1.96 | 17.52 | 33.30 | 40.03 | 59.31 | 133.92 | 152.77 | 165.21 | 198.19 | 222.39 | 253.28 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.4M | $22.1M | $24.3M | $49.8M | $22.9M | $34.0M | $52.1M | $26.6M | $15.1M | $33.2M | $38.8M | |
| Marketable Securities | $0.00 | $72.2M | $86.5M | $72.0M | $59.3M | $127.2M | $73.8M | $135.7M | $181.2M | $202.5M | $164.0M | |
| Total Current Assets | $14.6M | $97.9M | $113.3M | $124.1M | $85.1M | $165.0M | $129.0M | $165.9M | $202.1M | $241.6M | $209.3M | |
| Total Assets | $28.9M | $159.6M | $152.3M | $136.2M | $97.7M | $176.6M | $139.8M | $177.6M | $212.9M | $253.4M | $221.6M | |
| Total Current Liabilities | $3.5M | $6.0M | $7.3M | $10.9M | $8.2M | $14.7M | $5.9M | $10.6M | $14.7M | $20.4M | $15.5M | |
| Long-Term Debt | $3.4M | $14.8M | $24.5M | $23.1M | $25.1M | $17.3M | $26.1M | $26.3M | $26.6M | $29.9M | $30.1M | |
| Total Liabilities | $64.8M | $40.3M | $44.1M | $34.5M | $33.4M | $32.1M | $32.0M | $37.2M | $41.4M | $50.3M | $45.6M | |
| Stockholders' Equity | $-35.9M | $119.3M | $108.2M | $101.7M | $64.4M | $144.5M | $107.8M | $140.4M | $171.4M | $203.1M | $176.0M | |
| Retained Earnings | $-38.4M | $-68.2M | $-129.7M | $-207.9M | $-257.5M | $-300.5M | $-338.7M | $-393.4M | $-489.3M | $-608.1M | $-645.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-8.4M | $-28.2M | $-39.3M | $-45.1M | $-39.8M | $-40.1M | $-34.6M | $-51.1M | $-89.1M | $-101.0M | $-106.9M | |
| Capital Expenditure | $-8.0K | $-495.0K | $-141.0K | $-148.0K | $-3.3M | $-57.0K | $-9.0K | $-296.0K | $-25.0K | $-22.0K | $-73.0K | |
| Free Cash Flow | $-8.4M | $-28.7M | $-39.4M | $-45.3M | $-43.1M | $-40.1M | $-34.6M | $-51.4M | $-89.1M | $-101.1M | $-107.0M | |
| Investing Cash Flow | $-8.0K | $-69.1M | $-13.6M | $15.7M | $9.1M | $-69.5M | $52.6M | $-57.1M | $-39.9M | $-18.4M | $-9.0M | |
| Financing Cash Flow | $5.1M | $106.1M | $55.2M | $54.9M | $3.7M | $120.8M | $87.0K | $82.8M | $117.6M | $137.8M | $135.3M | |
| Issuance of Stock | $0.00 | $91.3M | $46.3M | $54.8M | $2.3M | $122.2M | $0.00 | $83.7M | $118.2M | $140.2M | $140.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-78.0K | $-3.0K | $-1.2M | $-995.0K | $-5.1M | $-5.2M | |
| Issuance of Debt | $4.4M | $14.9M | $9.4M | $0.00 | $0.00 | $0.00 | $26.4M | $0.00 | $0.00 | $29.6M | $0.00 | |
| Payments of Debt | $-81.0K | $-460.0K | $-546.0K | $-41.0K | $-514.0K | $0.00 | $-26.4M | $0.00 | $0.00 | $-27.2M | $1.0K | |
| Stock Based Comp. | $209.0K | $552.0K | $3.7M | $4.4M | $5.1M | $3.3M | $2.0M | $4.2M | $9.9M | $14.4M | $22.2M | |
| Net Change in Cash | $-3.3M | $8.7M | $2.2M | $25.5M | $-26.9M | $11.1M | $18.1M | $-25.5M | $-11.5M | $18.1M | $19.2M |
Dilution Tracker
Shares outstanding grew 89.1% over 5 years — significant dilution
Shares Outstanding
253M
5-Year Share Growth
+89.1%
Stock Issuance (TTM)
$140.2M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.96 | 17.52 | 33.30 | 40.03 | 59.31 | 133.92 | 152.77 | 165.21 | 198.19 | 222.39 | 253.28 | |
| YoY Change % | — | 793.9% | 90.1% | 20.2% | 48.2% | 125.8% | 14.1% | 8.1% | 20.0% | 12.2% | 13.9% | |
| Stock Issuance | $0.00 | $91.3M | $46.3M | $54.8M | $2.3M | $122.2M | $0.00 | $83.7M | $118.2M | $140.2M | $140.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-78.0K | $-3.0K | $-1.2M | $-995.0K | $-5.1M | $-5.2M | |
| Stock Based Comp. | $209.0K | $552.0K | $3.7M | $4.4M | $5.1M | $3.3M | $2.0M | $4.2M | $9.9M | $14.4M | $22.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | -2737.0% | 0.0% | 0.0% | 0.0% | -18835.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | -2730.8% | 0.0% | 0.0% | 0.0% | -19305.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | -2620.5% | 0.0% | 0.0% | 0.0% | -18459.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | -2094.5% | 0.0% | 0.0% | 0.0% | -16782.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | -71.4% | -54.1% | -74.5% | -59.7% | -41.2% | -30.2% | -44.1% | -61.5% | -63.5% | -87.3% | |
| ROA % | -26.3% | -31.6% | -39.4% | -54.2% | -42.4% | -31.4% | -24.1% | -34.5% | -49.1% | -51.0% | -66.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical6.68 / 330.00 / 1871.70
Industry Med.9.49
P/B7.02
Historical0.24 / 1.97 / 8.20
Industry Med.2.93
EV/EBITDA-7.99
Historical-20.75 / -3.92 / 34.11
Industry Med.13.02
EV/Revenue—
Historical-199.39 / 413.55 / 3501.33
Industry Med.8.59
P/FCF—
Historical0.49 / 1.75 / 6.59
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$0.80
Net Current Assets
$0.800
Net-Net Working Capital
$0.77
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 29.78 | - | - | - | 287.50 | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 3.80 | 2.46 | 2.24 | 0.97 | 0.98 | 1.64 | 4.63 | 3.09 | 6.07 | 7.02 | |
| EV/EBITDA | -1.26 | -12.63 | -3.88 | -1.70 | -0.11 | -0.15 | -2.03 | -8.68 | -3.52 | -8.38 | -7.99 | |
| EV/Revenue | 33.02 | 0.00 | 0.00 | 0.00 | 20.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $2M | $111M | $278M |
| Net Income | $0M | $0M | $0M |
| EPS | -0.57 | -0.18 | 0.36 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2020 |
|---|---|
| Specialty pharmaceuticals within the respiratory system | $257.0K |
By Geography
| Segment | 2020 |
|---|---|
| United States | $257.0K |